Ensuring that Alzheimer’s disease (AD) clinical trials reflect real-world patient populations remains a key challenge, as eligibility criteria can unintentionally influence who is able to participate. A recent study published in The Journal of Prevention of Alzheimer’s Disease examines how commonly used trial inclusion criteria shape participant selection, with a focus on differences observed between men and women in a clinic-based cohort. The research brings together an international team of investigators, including Lieza G. Exalto, Senior Vice President, Neuroscience Medical at P95 Julius Clinical, highlighting the organization’s continued contribution to advancing rigorous and inclusive clinical research.

Read the full study →

The findings indicate that several widely applied eligibility criteria may disproportionately affect representation, with implications for the generalizability of study outcomes. By identifying these patterns, the study underscores the importance of designing eligibility frameworks that better capture the diversity of patients seen in clinical practice. The involvement of Exalto reflects P95 Julius Clinical’s broader commitment to improving study design and supporting evidence-based approaches that help ensure more representative research and, ultimately, better outcomes for individuals affected by Alzheimer’s disease.